ETNB(Delisted)
89bio (ETNB) Stock Statistics, Valuation & Financial Metrics
Total Valuation
89bio market cap is -- and enterprise value is --.
Share Statistics
89bio has 148.31M shares outstanding, with a free float of 145.98M.
Valuation Ratios
89bio's PE ratio is --, PB ratio is --, and PS ratio is --, showing whether the stock looks expensive or cheap.
Liquidity
89bio's current ratio is 15.19, quick ratio is 15.19, and cash ratio is 14.17, showing its short-term liquidity position.
Return on Capital
89bio's ROE is -86.86%, ROA is -75.94%, and ROIC is -85.07%, showing its return on capital profile.
Profitability
89bio gross margin is --, operating margin is --, and net margin is --.
Operating Efficiency
89bio's asset turnover is 0, inventory turnover is --, and receivables turnover is --, indicating its operating efficiency.
Income Statement
89bio's revenue is --, gross profit is --, net income is -450.21M, and EBITDA is -474.34M.
Balance Sheet
89bio's total debt is 36.16M, net debt is -525.01M, total equity is 521.73M, and cash is 561.16M.
Cash Flow Statement
89bio's operating cash flow is -439.10M, free cash flow is -439.19M, and CapEx is --.
Dividends & Yields
89bio dividend yield is --, with a payout ratio of -- and dividend per share of --.
Analyst Rating
89bio's latest analyst rating is Unrate, with an analyst target price of --.
Company Info
A biopharmaceutical company focused on developing and commercializing innovative therapies for liver and metabolic disorders
Per Share Metrics
89bio's EPS is -3.69, book value per share is 3.52, and free cash flow per share is --.
